Stephen W. Reese, MD
@sreese_uromd
Followers
73
Following
69
Media
2
Statuses
19
SUO Urologic Oncology Fellow @UrologyMSK. Graduate of @bwhurology. Views expressed herein are my own.
Joined May 2022
Looking for an “all things prostate” job, easy call, two teams of residents, loan repayment and great benefits? We are 5 full time urologists looking for a 6th, with 5 APP staff and 4 residents on service at all times. Check us out! https://t.co/o2Io5vKVBS
1
4
17
Congratulations to our stellar class of 2024! Was a special day and even a more special night! @MSKCancerCenter
1
8
65
Congrats to @MTDawidek and @sreese_uromd on winning best poster for their work with radiologic predictors of pathologic response in post IO cytoreduction! #AUA24
2
4
28
Now published in @JUrology by @UrologyMSK Stephen Reese @sari_safaa Jonathan Coleman, Paul Russo @arihakimi et al. Prognostic factors for survival in patients undergoing surveillance after cytoreductive nephrectomy https://t.co/VBmJt9pYIG
auajournals.org
Purpose:The clinical course of patients being placed on surveillance in a cohort of systemic therapy–naïve patients who undergo cytoreductive nephrectomy is not well documented. Thus, we evaluated...
0
2
9
Institutional trends @BWHUrology @FaulknerHosp for same-day robot-assisted radical prostatectomy #ProstateCancer ➡️Makes ~ 50% of our cases ➡️No increase in complications or readmissions ➡️May soon become standard practice Full article https://t.co/aBlk4t8wW9
4
7
29
Amazing time with our clinical fellows at our annual robotics training course! Special thanks to course organizers @alvincgoh and Jonathan Coleman
1
6
47
Annual open surgical skills training program (Day 1) for @UrologyMSK fellows finishing research year. Great hosts @hartfordhosp CESI center, urology and vasc surgery @bca_md @DrAndrewKatims @KellyPekalaMD @Shindebr @sreese_uromd @CGaffMD @AliMouzannar11
1
8
51
Characterization of patients undergoing consolidative nephrectomy after immunotherapy. Presented by Stephen Reese, MD @MultiCareHealth. #IKCSNA22 written coverage by @WallisCJD @UofT > https://t.co/tjs3rvORqL
@KidneyCancer
0
5
8
Excellent weekend getting a masterclass in TURBT with @bbmdmsk. The practice models were truly unbelievable!@Olympus_Corp @UrologyMSK @CGaffMD @DrAndrewKatims @dralisamir @Shindebr
0
4
24
Now published in @Cancers_MDPI by @UrologyMSK Lina Posada Calderon, Lennert Eismann, Stephen W Reese @arihakimi et al.: Advances in imaging-based biomarkers in renal cell carcinoma: A critical analysis of the current literature https://t.co/wI9ZZQFrZB
mdpi.com
Cross-sectional imaging is the standard diagnostic tool to determine underlying biology in renal masses, which is crucial for subsequent treatment. Currently, standard CT imaging is limited in its...
0
4
13
Great to see this amazing work from wonderful co-fellows. #GU23 @DrAndrewKatims @Cgaffmd @UrologyMSK
0
3
23
Checkmate-914 (adjuvant nivo/ipi) vs placebo in high-risk Kidney Cancer is out in the @TheLancet: the study is negative with no DFS/OS advantage. 33% disc. for toxicity could be the main culprit. Thank you for all the patients/families who believe in https://t.co/7Sz537vWWU
2
47
181
Now published in @UrologicClinics by @UrologyMSK Stephen Reese @sari_safaa @arihakimi et al.: Current and future biomarkers in the management of renal cell carcinoma https://t.co/ElCS0NlTFO
0
1
4
JUST IN: Cytoreductive Nephrectomy for Metastatic RCC Treated with Immune Checkpoint Inhibitors or Targeted Therapy: The @IMDConline does it again ! #IMDC @DrDanielHeng with @TalalZarif1 @ZiadBakouny @ShaanDudani et al in @EUplatinum
https://t.co/1DSzGz1cEJ
7
99
265
Interested in learning more about the oldest and largest @UroOnc fellowship? Come join us at our virtual open house Wednesday Nov 16th 7 pm EST. https://t.co/GliRQwt4mx (zoom link to follow)
docs.google.com
Open House 2022
1
12
21
EV-103 Dose Esc/Cohort A Confirmed ORR after 9 cycles 73.3% with a 15.6% complete response rate. Median DOR 25.6 mo, median OS 26.1 mo. Cohort K coming Sep 12. @DrChrisHoimes @TomFlaigMD @shilpaonc @DrRanaMcKay @MattMilowsky @MSKCancerCenter @JCO_ASCO
ascopubs.org
PURPOSECisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial, responses are rarely...
6
65
176
Looking forward to Alex rejoining our team. Thanks to CU for all the patients in Boston who will benefit from your teaching. @BWHUrology
Congratulations to Alexandra Berger Eberhardt, MD the 14th graduate from CU recon urology fellowship! Brigham & Women's Hospital is fortunate to have you return. @adamkibel_uro
@CU_Urology
@T_T_Higuchi
@drdanwood
@KirkRedger
@DavidKoslov
@HVillarrealMD
@blakelyGU
@UroRecon
0
2
10